Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M

GLAUKOS Corp

2024-Q1 EPS reported -$0.82 revenue$85,622,000

Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).
GAAP gross margin 76%; non-GAAP gross margin 83%.
GAAP net loss per share ($0.82); non-GAAP net loss per share ($0.70) includes $11.7M IPR&D charge.
Raised 2024 net sales guidance from $350-$360M to $357-$365M.
Cash and investments ~$279M at quarter end.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported first quarter ended March 31, 2024 results: revenue $85.6 million, net income ($40.8 million), EPS ($0.82) per diluted share. Guidance raised.

Period: first quarter ended March 31, 2024
Revenue: $85.6 million
Net income: ($40.8 million)
EPS: ($0.82) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: ● Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. ● Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. ● Corneal Health net sales of $18.4 million in Q1

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-006383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.